drugset / Trial / NCT00856583

Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use

NCT00856583

Phase 3 Completed 9809 enrolled H. Lundbeck A/S
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of the study is to determine whether there is an increased all-cause mortality in sertindole-treated patients in comparison to patients treated with a well-known antipsychotic (risperidone) when used under normal marketed conditions in the treatment of schizophrenia.

Timeline

Start
2002-07
Primary completion
2008-02
Completion
2008-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Risperidone Other / unclassified 1 mg
Comparator Risperidone Other / unclassified 2 mg
Comparator Risperidone Other / unclassified 3 mg
Comparator Risperidone Other / unclassified 4 mg
Comparator Risperidone Other / unclassified 8 mg
Subject Sertindole Small molecule 4 mg
Subject Sertindole Small molecule 12 mg
Subject Sertindole Small molecule 16 mg
Subject Sertindole Small molecule 20 mg
Subject Sertindole Small molecule 24 mg

Indications